November trading, Berkshire's cash hoard, Big Tech's ad revenue and more in Morning Squawk

As the trading day commences, investors are greeted with positive stock futures, signaling a fruitful start to November. Following a successful October, driven largely by the ongoing interest in artificial intelligence, market momentum appears strong. Berkshire Hathaway has reached a new milestone with its cash reserves climbing to an impressive $381.6 billion, surpassing its previous high of $347.7 billion. This increase comes despite CEO Warren Buffett's decision against share buybacks, even as the company's stock has experienced a significant drop since May. In the third quarter, Berkshire reported a remarkable $13.485 billion in operating profit from its wholly owned businesses, marking a 34% rise year-over-year, fueled largely by a 200% surge in income from its insurance underwriting sector. Overall, the company's earnings increased by 17%, totaling $30.8 billion. Meanwhile, the tech sector displayed resilience as the members of the Magnificent Seven exceeded revenue expectations in their latest earnings reports. Notably, digital advertising revenue has remained robust, with major players like Meta, Amazon, Alphabet, and Microsoft reporting strong sales figures. This indicates that, despite economic uncertainties, advertising budgets are holding steady, contrary to earlier fears. Big Tech's investment in AI remains unshaken, with the four leading companies anticipating capital expenditures to surpass $380 billion this year. Microsoft CEO Satya Nadella shared insights on a recent podcast, emphasizing how AI will enable the company to expand its workforce more efficiently. In a related note, a federal judge mandated that the Trump administration utilize emergency funds to continue providing SNAP food benefits amid the ongoing government shutdown. With 42 million Americans relying on these benefits, the administration is expected to comply without appeal, ensuring these vital resources remain accessible. In the pharmaceutical sector, Eli Lilly and Novo Nordisk are currently the dominant players in the weight loss and diabetes drug market, which could reach a staggering $100 billion by 2030. New competitors are emerging, but both firms are taking measures to maintain their leading positions by enhancing supply and exploring new applications for their medications. Novo Nordisk, facing a challenging year with a nearly 40% drop in shares, is hoping for a turnaround under new leadership. Investors should stay tuned this week as economic data releases may be delayed due to the government shutdown. Keep an eye on the key reports and events that could shape market dynamics in the days ahead.